Journal ArticleDOI
Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes.
Abby R. Saniabadi,Hiroyuki Hanai,Ken Takeuchi,Kazuo Umemura,Mitsuyoshi Nakashima,Taro Adachi,Chikako Shima,Ingvar Bjarnason,Robert Löfberg +8 more
TLDR
A long lasting effect on inflammatory cytokine generation,chemokine activities or immunomodulation is likely, but the precisemechanisms involved are not fully understood yet.Abstract:
Apheresis has been recognized both economically and therapeutically as a novel approach for the treatment of inflammatory diseases, and certain others, which respond poorly to drug therapy. This report is about Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device with a volume of 335 mL, filled with about 220 g of cellulose acetate beads of 2 mm diameter as the column adsorptive carriers. Pre- and post-column leukocyte counts have shown that the carriers adsorb about 65% of granulocytes, 55% of monocytes and 2% of lymphocytes from the blood in the column. Additionally, after apheresis, there is a marked decrease in inflammatory cytokines (TNF-alpha, IL-1beta, IL-6 and IL-8) produced by blood leukocytes, together with down-modulation of L-selectin and the chemokine receptor CXCR3. Adacolumn has been used to treat patients with rheumatoid arthritis, ulcerative colitis and HIV infection. Typical apheresis sessions have been 4-10, at a frequency of one or two sessions per week. Treatment of patients with Adacolumn has been associated with very promising efficacy and safety data. Accordingly, in Japan, Adacolumn has been approved by the Ministry of Health for the treatment of ulcerative colitia. Furthermore, Adacolumn met the required quality and safety standards for medical devices and received an EC certification (CE-mark) from TUV in 1999. However, although Adacolumn carriers are very efficient in depleting excess and activated granulocytes and monocytes/macrophages, the clinical efficacy associated with Adacolumn apheresis cannot be fully explained on the basis of reducing granulocytes and monocytes per se. Hence, a long lasting effect on inflammatory cytokine generation, chemokine activities or immunomodulation is likely, but the precise mechanisms involved are not fully understood yet.read more
Citations
More filters
Journal ArticleDOI
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the writing committee of the american society for apheresis
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence‐based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the “level of evidence” criteria.
Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.
Zbigniew M. Szczepiorkowski,Jeffrey L. Winters,Nicholas Bandarenko,Haewon C. Kim,Michael L. Linenberger,Marisa B. Marques,Ravindra Sarode,Joseph E. Schwartz,Robert Weinstein,Beth H. Shaz +9 more
TL;DR: The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions and a new concept of a fact sheet has been introduced that succinctly summarizes the evidence for the use of therapeutic apheresis.
Journal ArticleDOI
A Randomized, Double-Blind, Sham-Controlled Study of Granulocyte/Monocyte Apheresis for Active Ulcerative Colitis
Bruce E. Sands,William J. Sandborn,Brian G. Feagan,Robert Löfberg,Toshifumi Hibi,Tao Wang,Lisa Marie Gustofson,Cindy J. Wong,Margaret K. Vandervoort,Stephen B. Hanauer +9 more
TL;DR: Granulocyte/monocyte apheresis was well tolerated but did not demonstrate efficacy for induction of clinical remission or response in patients with moderate-to-severe ulcerative colitis.
Neutrophil apoptosis is delayed in patients with inflammatory bowel disease
Ann E. Brannigan,P. R. O'Connell,H. Hurley,Amanda O'Neill,Hugh R. Brady,John M. Fitzpatrick,R. W. G. Watson +6 more
TL;DR: In this article, the authors studied 20 patients with IBD, 13 with Crohn's disease, and 7 with ulcerative colitis, all of whom were undergoing intestinal resection for symptomatic disease.
References
More filters
Journal ArticleDOI
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
TL;DR: It is concluded that oral 5-ASA administered in a dosage of 4.8 g per day is effective therapy, at least in the short term, for mildly to moderately active ulcerative colitis.
Journal Article
International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors
Philip M. Murphy,Marco Baggiolini,Israel F. Charo,Caroline A. Hébert,Richard Horuk,Kouji Matsushima,Louis H. Miller,Joost J. Oppenheim,Christine A. Power +8 more
TL;DR: A widely accepted receptor nomenclature system is described, ratified by the International Union of Pharmacology, that is facilitating clear communication in this area and updating current concepts of the biology and pharmacology of the chemokine system.
Journal ArticleDOI
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
TL;DR: Mesalazine coated with Eudragit L is a safe, logical alternative to sulphasalazine in patients with active mild to moderate ulcerative colitis and remission rates were 74% and 81% in the two treatment groups respectively.
Journal ArticleDOI
The production of cytokines by polymorphonuclear neutrophils
TL;DR: Novel facets of the regulation of cytokine production by PMN are described that highlight the involvement of of PMN in cell-cytokine crosstalk.
Journal ArticleDOI
Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators.
TL;DR: Inhibition of apoptosis of aging neutrophil populations was associated with prolongation of the functional life span of the population as assessed by the ability of neutrophils to spread on glass surfaces, to polarize in response to deliberate stimulation with N‐formyl‐Met‐Leu‐Phe, and to release the granule enzyme marker myeloperoxidase on fMLP stimulation.
Related Papers (5)
Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study.
Takashi Shimoyama,Koji Sawada,Nobuo Hiwatashi,Toshio Sawada,Kei Matsueda,Akihiro Munakata,Hitoshi Asakura,Takao Tanaka,Reiji Kasukawa,Ken Kimura,Yasuo Suzuki,Yukio Nagamachi,Tetsuichiro Muto,Hirokazu Nagawa,Bunei Iizuka,Shozo Baba,Masaru Nasu,Tatsuji Kataoka,Nobuhito Kashiwagi,Abby R. Saniabadi +19 more